# US 2026/0007682 A1 · Nasal compositions comprising alcaftadine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007682 A1
- Document ID: US20260007682A1
- Status: Published application
- Kind: A1
- Application number: 19/087,084
- Filed: 2025-03-21
- Published: 2026-01-08
- Earliest claimed: 2021-04-01
- Assignees: Alkem Laboratories Limited
- Applicants: Alkem Laboratories Limited
- Inventors: Akhilesh SHARMA; Babasaheb AWARE; Viraj SHAH; Amol AIWALE
- Web page: https://patentgrep.com/patent/US20260007682A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 11/02: Nasal agents, e.g. decongestants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method of treating allergic rhinitis in a human patient in need thereof comprising nasally administering to the patient an effective amount of an aqueous pharmaceutical composition comprising about 0.125% to about 0.5% w/w alcaftadine or a pharmaceutically acceptable salt thereof and a mucoadhesive agent.

### Claim 26 (depends on 25)

The method of claim 25, wherein the alcaftadine is in free form.

### Claim 27 (depends on 25)

The method of claim 25, wherein the mucoadhesive agent is selected from hydroxypropylmethyl cellulose, hydroxyethylcellulose, carboxymethylcellulose sodium, povidone, chitosan, guar gum, xanthan gum, and any combination of any of the foregoing.

### Claim 28 (depends on 25)

The method of claim 25, wherein the mucoadhesive agent is hydroxypropylmethyl cellulose.

### Claim 29 (depends on 25)

The method of claim 25, wherein the composition further comprises a preservative.

### Claim 30 (depends on 25)

The method of claim 25, wherein the composition further comprises at least 0.0125% w/w benzalkonium chloride, based upon the total weight of the composition.

### Claim 31 (depends on 25)

The method of any claim 25, wherein the composition further comprises a buffering agent, a tonicity adjustment agent, a chelating agent, or any combination of any of the foregoing.

### Claim 32 (depends on 31)

The method of claim 31, wherein the buffering agent is monobasic sodium phosphate.

### Claim 33 (depends on 31)

The method of claim 31, wherein the tonicity adjustment agent is sodium chloride.

### Claim 34 (depends on 31)

The method of claim 31, wherein the chelating agent is disodium edetate.

### Claim 35 (depends on 25)

The method of claim 25, wherein the viscosity of the composition is from about 1.5 to about 4.0 cPs.

### Claim 36 (depends on 25)

The method of claim 25, wherein the pH of the composition is from about 6.3 to about 7.3.

### Claim 37 (depends on 25)

The method of claim 25, wherein the patient suffers from seasonal allergic rhinitis.

### Claim 38 (depends on 25)

The method of claim 25, wherein the patient suffers from perennial allergic rhinitis.

### Claim 39

A method of treating allergic rhinitis in a human patient in need thereof comprising nasally administering once or twice daily to each nostril of the patient about 171.25 to about 685 mcg alcaftadine or a pharmaceutically acceptable salt thereof, wherein the alcaftadine or a pharmaceutically acceptable salt thereof is administered in the form of an aqueous pharmaceutical composition comprising about 0.125% to about 0.5% w/w alcaftadine or a pharmaceutically acceptable salt thereof and a mucoadhesive agent.

### Claim 40 (depends on 39)

The method of claim 39, wherein the alcaftadine is in free form.

### Claim 41 (depends on 39)

The method of claim 39, wherein the viscosity of the composition is from about 1.5 to about 4.0 cPs.

### Claim 42 (depends on 39)

The method of claim 39, wherein the pH of the composition is from about 6.3 to about 7.3.

### Claim 43 (depends on 39)

The method of claim 39, wherein the alcaftadine or a pharmaceutically acceptable salt thereof is administered once daily.

### Claim 44 (depends on 39)

The method of claim 39, wherein the alcaftadine or a pharmaceutically acceptable salt thereof is administered twice daily.

### Claim 45 (depends on 39)

The method of claim 39, wherein the patient suffers from seasonal allergic rhinitis.

### Claim 46 (depends on 39)

The method of claim 39, wherein the patient suffers from perennial allergic rhinitis.
